University of California, San Diego
This is a single-center clinical study to investigate the efficacy of a Food and Drug Administration-approved analgesic, suzetrigine, to treat pain following non-mastectomy breast surgery in concert with a single-injection paravertebral nerve block.
Following written, informed consent, the investigators will collect baseline anthropomorphic information (e.g., age, sex, height, and weight). For individuals of childbearing potential, a sample of urine will be collected before any study interventions to confirm a non-pregnant state (this is standard procedure for all surgical patients). The University of California San Diego Investigational Drug Service will distribute the study medication (suzetrigine) to the investigators (7 suzetrigine tablets, each 50 mg) and labeled with the appropriate dosing. The first dose of study medication (2 tab…
Inclusion Criteria: 1. Adult participants of at least 18 years of age 2. Undergoing uni-or bilateral surgical procedures of the breast(s) anticipated to result in at least moderate pain (NRS \> 3) 3. Planned single-injection peripheral nerve block(s) Exclusion Criteria: 1. Chronic opioid or tramadol use (daily within prior 2 weeks and duration \> 4 weeks) 2. Neurological deficit of the surgical area 3. History of opioid misuse or dependence 4. Renal impairment with a GFR\<15 5. Hepatic impairment (Child-Pugh Class B or C) 6. Use of a moderate or strong CYP3A inhibitor in the week before or…
A total of seven 50 mg tablets of suzetrigine administered preoperatively.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.